In 2017, Domain Therapeutics and Pfizer (New-York, USA) signed a collaboration agreement to accelerate the validation of novel GPCR drug targets using bioSens-All™.

Domain Therapeutics will use its proprietary platform to profile signalling signature of multiple wild-type GPCRs and a large number of corresponding mutated GPCRs. This extensive characterization campaign will allow the correlation between the impact of point mutations on the intracellular signalling and consequence on the emergence of pathologies. These data will bring valuable information to guide future drug discovery efforts to restore the appropriate signalling signature (see press release).